These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27265969)

  • 1. Biosimilar Research Proceeds in Cancer, RA, and Hep B.
    Adams KT
    Manag Care; 2016 Apr; 25(4):35-7. PubMed ID: 27265969
    [No Abstract]   [Full Text] [Related]  

  • 2. [First biosimilar infliximab approved].
    Neumaier J
    MMW Fortschr Med; 2015 Mar; 157 Suppl 1():88. PubMed ID: 26013000
    [No Abstract]   [Full Text] [Related]  

  • 3. Biosimilars for the management of rheumatoid arthritis: economic considerations.
    Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current situations and the future prospect of monoclonal antibody products].
    Yamaguchi T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):36-46. PubMed ID: 25707201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
    Yoo DH; Oh C; Hong S; Park W
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S15-24. PubMed ID: 26395833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar drugs, myths and reality.
    Hernández-García C
    Reumatol Clin; 2014; 10(6):351-2. PubMed ID: 25037069
    [No Abstract]   [Full Text] [Related]  

  • 9. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
    Müller-Ladner U; Hong S; Oh C; Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fear of safety compromise with biosimilar anti-VEGF-perception or truth.
    Sharma A; Parachuri N; Kumar N; Bandello F; Kuppermann BD
    Eye (Lond); 2022 Nov; 36(11):2086-2087. PubMed ID: 35618752
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.
    Scheinberg M; Castañeda-Hernández G
    Arthritis Res Ther; 2014 Dec; 16(6):501. PubMed ID: 25677586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
    Thill M
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients.
    Ballanti E; Conigliaro P; Chimenti MS; Kroegler B; Di Muzio G; Guarino MD; Triggianese P; Gigliucci G; Novelli L; Barbato C; Perricone R
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S42-5. PubMed ID: 25381975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis therapy moves beyond cancer.
    Wilson JF
    Ann Intern Med; 2004 Jul; 141(2):165-8. PubMed ID: 15262679
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus.
    Zhang X; Zhang F; Wu D; Bao C; Zhu P; Zhang X; Huang C; He D; Tao Y; Fang Y; Gu J; Wu H; Sun L; Yang X; Huang F; Xu H; Zhao D; Zhang M; Zheng Y; Li Z
    Int J Rheum Dis; 2013 Aug; 16(4):408-12. PubMed ID: 23992260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research progress on B cell surface molecules targeted therapy in rheumatoid arthritis].
    Di W; Chang Y; Wu YJ; Wei W
    Sheng Li Ke Xue Jin Zhan; 2011 Jun; 42(3):175-80. PubMed ID: 21932514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development and trial design of biosimilar products: a Japanese perspective.
    Nagasaki M; Ando Y
    J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The advent of biosimilars: challenges and risks.
    Müller R; Renner C; Gabay C; Cassata G; Lohri A; Hasler P
    Swiss Med Wkly; 2014; 144():w13980. PubMed ID: 24984255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preface: issues in biosimilar drug development.
    Yao B; Chi E
    J Biopharm Stat; 2014; 24(6):1137. PubMed ID: 25360866
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical trial development for biosimilars.
    Alten R; Cronstein BN
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.